Open Access Articles | A Network Integration Method for Deciphering the Types of Metabolic Pathway of Chemicals with Heterogeneous Information

Author(s): Zi-Han Guo, Lei Chen*, Xian Zhao.

Journal Name: Combinatorial Chemistry & High Throughput Screening

 

A metabolic pathway is an important type of biological pathway, which is composed of a series of chemical reactions. It provides essential molecules and energies for living organisms. To date, several metabolic pathways have been uncovered. However, their completeness is still on the way. A number of prediction methods have been built to assign chemicals into certain metabolic pathway, which can further be used to predict novel latent chemicals for a given metabolic pathway. However, they did not make use of chemical properties in a system level to construct prediction models. Read out full article here: http://www.eurekaselect.com/168115

 

Most Accessed Articles | Extracranial-to-Intracranial Bypass for Pressor Dependent Cerebrovascular Insufficiency: Modified Classification and Representative Case

While some randomized clinical trials have reduced the indications for cerebral revascularization in the secondary prevention of ischemic stroke, a distinct subset of patients with blood pressure augmentation dependent cerebrovascular insufficiency due to large vessel occlusions remains unaddressed. With the recent paradigm shifts in acute ischemic stroke care, the role of extracranial to intracranial (EC-IC) bypass must be re-addressed when endovascular intervention is not a feasible option. We submit a refined classification of cerebrovascular insufficiency with a category called Pressor-Dependent Cerebrovascular Insufficiency (PD-CVI) for whom EC-IC bypass may be indicated. Read out full article here: http://www.eurekaselect.com/163730

 

Article by Disease | Therapeutic Utilities of Pediatric Cardiac Catheterization

 

Bentham Cardiovascular Disorders Collection | Cardiovascular Disorders | Aortic Coarctation 

Therapeutic cardiac catheterization constantly evolves and widens its spectrum of usage in the pediatric population. The advent of sophisticated devices and well-designed equipment has made the management of many congenital cardiac lesions more efficient and safer, while providing more comfort to the patient.

 

 

Read out more at: http://www.eurekaselect.com/node/139921/article

Press Release | Phytochemistry, traditional uses and pharmacological profile of rose hip

 

The genus Rosa from family Rosaceae is one of the most widespread species from the family. One species, rose hip (rose haw), is known as a good source of different types of micronutrients and phytochemicals such as phenolic acids, tannins, and flavonoids. It is known as a traditional treatment in folk medicine. It has been used for the treatment of several illness including ear, nose, and throat problems since old times.

This article by Dr. Amirhossein Sahebkar et al. is published in Current Pharmaceutical Design, 2018. To obtain the article, please visit: http://www.eurekaselect.com/166136

 

Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2018-12/bsp-ptu122718.php

Bentham Science Media Partnership with ENMORE BIO CONFERENE (2019 EBC) | Article Express by Media Partners

CHINA BIO INDUSTRY EXPLOSION ! WHAT ARE YOU WAITING FOR? COME TO CHINA, SEE THE CHANGE!

 

Recently, breakthroughs in China’s bio-industry have spread frequently

1. Monoclonal antibodies to Terepril monoclonal antibody and Sindelimab, the PD1 drug of Junshi Biology, are on the market in China, respectively.
2. Five of them have received IND approval in China, and about 30 have submitted applications for IND approval. With the continuous standardization of the policy of the cell therapy industry in China, 2019 is an important year.
3. Breakthrough Records of Financing News for Bio-industry Enterprises
4. Diagnosis in the second half of 2018, Fuel Stone Medicine was approved as “the first certificate of NGS in China”, and after that, Noah Origin, Nanjing Shihe and Xiamen Aide were approved as multi-target NGS tumor kits.
5. In the second half of 2018, Wondfo and Biocartis Company established a joint venture, and KH Biology cooperated with Seegene from Korea.
6. Domestic molecular diagnostics and gene testing companies cooperate frequently with overseas companies to promote the commercialization of molecular diagnostics in the field of cancer in China.

 

Based on the progress of China’s bio-industry in 2018, the 4th EBC came into being. China’s veteran bio-industry Congress will be held in Nanjing, the ancient capital of China, from March 1 to 3. Welcome the global bio-industry related enterprises to come.

 

2019 ENMORE BIO CONFERENCE

Official website: http://ebc.enmorebiz.com/english.html

ORGNIZATOR: ENMORE HEALTHECARE

CO-HOST：3S Bio, 3D MED, FosunKite, IQVIA, I-MAB,Hrain, Dian Diagnostics,

Bring together:

• 9th Antibody Drugs & Novel Biological Summit
• 7th Molecular Diagnostics Summit
• 5th Immunotherapy Industry Summit
• 2nd Financing and Investment leadership Summit

2500+ Delegates

108+ speech slots

11+ Panel

5+ Industry analysis and roundtable

150+ Special guests

200+ Booth (CROCMO area, meeting area)

 

IMPORTANT SPEECHES:

Antibody and Novel

 “China Vision-New drug development and R&D strategy”

LianshanZhang, VP&GlobalR&D director, Jiangsu HengruiPharma

 

“How to choose partners to promote product process”

CuiyunXu, Henlius

 

ATTENDEE LIST

3S Bio	3D MED	I-MAB	INNOVENBIO	ZAI Lab	Wuxi Biologics	Junshi	Henlius
Bio-thera	Alphamab	Genscript	Akeso	Beigene	Chempartner	Legend	Pfize

 

Cell Therapy

“Engineer CAR-T cells for improving cancer immunotherapy”

YarongLiu, R&D Director, HRAIN Biotechnology

“CRISPR/Cas9genomeeditinginTcellsanditsapplicationinadoptivecelltherapy”

YanniLin, CTO & Co-founder, Cure Genetics Co.

 

ATTENDEE LIST

Dasheng Bio	CarsgenTheraputic	Unicar-Therapy	ThermoFisher
Immunochina	LegendBiotech	FosunKite	JWTherapeutics
Genscript	TongjiHospital	SMMU	Iasobio
Wuxi	CBMG	EUREKA Therapeutics,Inc	XPH

 

Diagnostics

 “China Molecular Diagnosis Industry Status and Future Market Growth from a Global View”

Chun Wu, CEO, BCG

“Development and application of molecular diagnostic products in vitro”

Tang Jiang, Chief Technical, Dian Diagnostics

 

ATTENDEE LIST

Dian Diagnostics	BCG	Grail	Jiangsu Provincial Inspection Center
West China Hospital	IDbyDNA	Thermo Fisher	Roche Diagnostics
Geneseeq	WeGene	Dipu Diagnostics	Genomics
Yunkang Health	CBMG	Daan Gene	Simcredex

For more information please contact (Deadline 30^th, Jan, 2019):

Brandon Huang

Tel: +86 (0) 21 51552421

Mb: 86-17701301812
Email: brandonhuang@enmore.com

 

 

Article by Disease | Statins in Aortic Disease

Bentham Cardiovascular Disorders Collection | Cardiovascular Disorders | Aortic Coarctation 

 

Abstract:

Background: Numerous studies indicate that statins have multiple beneficial actions (known as ‘pleiotropic actions’) on cardiovascular system through the improvement of endothelial dysfunction, inflammation, oxidative stress, excessive arterial thrombosis, and stabilization of the atherosclerotic plaque. Aortic disease primarily consists of aortic valve stenosis, aortic valve regurgitation, aneurysm disease, and genetic disorders such as Marfan syndrome, bicuspid aortic valve and aortic coarctation. Many studies have revealed the cardioprotective actions of statins in aortic disease.

Objective: Our aim was to present current data concerning the value of treatment with statins in aortic diseases.

Methods: A thorough search of PubMed and the Cochrane Database was conducted to identify the studies and novel articles related to the use of statins in aortic disease.

Results: Numerous studies in animals and humans indicate a beneficial effect of treatment with statins in the previous conditions apart from a few conflicting data.

Conclusion: There is a need of further investigation in this field, especially for the estimation of the optimal type and dose of statins required in each clinical condition of aortic disease.

 

Read out more at: http://www.eurekaselect.com/node/157165/article

Press Release | Genetic polymorphisms and zinc status

 

This article by Dr. Angela Polito et al. is published in Current Pharmaceutical Design, 2018

 

Zinc is one of the essential components in the diet of all living organisms. It is the second most abundant biological trace element after iron. Zinc is of great importance in various metabolic functions and its deficiency can cause many problems. It is involved in cellular metabolism, growth, development, cellular physiology, and immune function. Approximately 300 enzymes and 100 transcription factors identified have the requirement of Zinc to remain functional. As a cofactor in enzymes, it ensures the catalytic activity of six main classes of enzymes including oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases.

Zinc has an essential pleiotropic role in human body and because of that, its concentration must remain constant and independent of dietary fluctuations. Zinc is mostly lost through urine and unavoidable skin and intestine cell desquamation and hair. In harsh conditions, it may be lost through perspirations. Together with the loss of fluids, this daily loss of zinc content should be replaced by the appropriate dietary intake. The homeostasis of Zinc is a well-regulated cellular process and has been reported to be chiefly mediated by the expression and activity of zinc-binding proteins such as metallothioneins and zinc transporters. Genes encoding for these proteins are known to exist as genetic variants.

A multi-database electronic research was conducted to provide an overview on the relationship between single nucleotide polymorphisms (SNPs) of genes encoding for metallothioneins and zinc transporters and their relationship with zinc status, immune function and some non-communicable diseases. It was found that some SNPs may affect the impact of Zinc supplementation on immune function, diabetes, and obesity. Further studies are required to clarify the interaction between individual genetic profile and zinc status. Moreover, there is a need for closer coordination between scientific bodies and health professionals to enable authorities to prescribe better dietary and behavioral recommendations to promote human health, with particular concern to elderly people.

 

 

The article is Open Access till 31st January, 2019. Browse the article details at: http://www.eurekaselect.com/166314

Press Release | Systematic review of food addiction as measured with the Yale Food Addiction Scale

 

This article by Dr. Louise Penzenstadler et al. is published in Current Neuropharmacology, 2018

 

 

Clinical food addiction diagnoses are nowadays measure by a tool called Yale Food Addiction Scale (YFAS) which was initially developed on the basis of criteria for identifying substance addictions. Yale Food Addiction Scale (YFAS) is used in different populations particularly, in obese patients who are planning for bariatric surgery. This systematic review covers literature published on food addiction diagnosis using PsycINFO, MEDLINE, and PsycARTICLES.databases from January 2014 and July 2017 (60 publications in total). Recent studies have been reviewed due to the introduction of YFAS 2.0, mYFAS in light of the debate on behavioral addictions.

The results of clinical and non-clinical samples with a higher body mass and incidence of eating disorders (EDs), shows higher scores of YFAS in binge eating disorder (BED).

The studies revealed that incidence of food addictions differs according to the population studied and this is dependent on sample selection methods. The criteria for differentiation of food addictions and other eating and addictive disorders can be made from the analysis of behavioral addictions. However, the authors of this review recommend that study groups should conduct further research in this field considering the psychological processes of obsessive eating in view of behavioral addictions. There are some limitations associated with YFAS item formulation and some items necessities to be examined in a different way in future studies. The studies must determine individual items of the scale to evaluate mechanisms from clinical perspective.

 

 

The article is Open Access till 31st January, 2019. Browse the article details at: http://www.eurekaselect.com/167164

Press Release | Cell death mechanisms in stroke and novel molecular and cellular treatment options

This article by Dr. Emine Sekerdag et al. is published in Current Neuropharmacology, Volume 16, Issue 9, 2018

 

The blood circulation to neurons is affected due to Ischemic, hemorrhagic stroke and subarachnoid hemorrhage stimulation the activation of pathophysiological responses i.e. mitochondrial death pathways, protein misfolding, apoptosis, pyroptosis, necrosis, autophagy, mitophagy, ferritinophagy, excitotoxicity, free radicals release, and inflammation. The review focuses on the recent updates in our knowledge about cellular death mechanisms caused by the loss of neuronal cells and astrocytes, damage to white matter.

Novel treatment preferences in stroke involves restoration of blood flow control and the applicability of treatments is restricted due to a limited bioactive time window of thrombolytic agents. Ischemic, hemorrhagic stroke and subarachnoid hemorrhage are discussed in this review in relation to novel molecular, cellular treatment alternatives and cellular death mechanisms.

Browse the article details at: http://www.eurekaselect.com/160188

Article by Disease | Notch Signaling in Normal and Disease States: Possible Therapies Related to Glycosylation

 

Bentham Cardiovascular Disorders Collection | Alagille Syndrome

 

 

 

Abstract:

The Notch signaling pathway is involved in a wide variety of highly conserved developmental processes in mammals. Importantly, mutations of the Notch protein and components of its signaling pathway have been implicated in an array of human diseases (T-cell leukemia and other cancers, Multiple Sclerosis, CADASIL, Alagille Syndrome, Spondylocostal Dysostosis). In mammals, Notch becomes activated upon binding of its extracellular domain to ligands (Delta and Jagged/Serrate) that are present on the surface of apposed cells. The extracellular domain of Notch contains up to 36 tandem Epidermal Growth Factor-like (EGF) repeats. Many of these EGF repeats are modified at evolutionarily-conserved consensus sites by an unusual form of O-glycosylation called O-fucose. Work from several groups indicates that O-fucosylation plays an important role in ligand mediated Notch signaling. Recent evidence also suggests that the enzyme responsible for addition of O-fucose to Notch, protein O-fucosyltransferase-1 (POFUT1), may serve a quality control function in the endoplasmic reticulum. Additionally, some of the O-fucose moieties are further elongated by the action of members of the Fringe family of β-1,3-N-acetylglucosaminyltransferases. The alteration in O-fucose saccharide structure caused by Fringe modulates the response of Notch to its ligands. Thus, glycosylation serves an important role in regulating Notch activity. This review focuses on the role of glycosylation in the normal functioning of the Notch pathway. As well, potential roles for glycosylation in Notch-related human diseases, and possible roles for therapeutic targeting of POFUT1 and Fringe in Notch-related human diseases, are discussed.

 

Read out more at: http://www.eurekaselect.com/node/59354/article